Published in final edited form as:

Gen Hosp Psychiatry. 2019 ; 60: 148–155. doi:10.1016/j.genhosppsych.2019.04.001.

New lung cancer treatments (immunotherapy and targeted therapies) and their associations with depression and other psychological side effects

Daniel C. McFarland, D.O.¹

¹Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, New York, NY

Abstract

Objective—Lung cancer carries a high prevalence of distress, anxiety and depression. New treatments, targeted therapy and immunotherapy have changed the disease course for subsets of patients, but their psychological associations and possible mechanisms of action (e.g., inflammation and physical symptoms) are not well described.

Method—Patients with metastatic lung cancer undergoing systemic treatment (n=109) were evaluated for distress and self-endorsed problems using the Distress Thermometer and Problem List and depression and anxiety using the Hospital Anxiety and Depression Scale. Demography, cancer-related information, and inflammation were evaluated for their associations with chemotherapy, targeted therapy, and immunotherapy.

Results—Chemotherapies were given most often followed by immunotherapy and targeted therapies. Depression and anxiety were endorsed by 23.9%, respectively, and 41.1% had significant distress. Chemotherapy was associated with greater depression (p=.006) and inflammation (p<.001). Physical symptoms were the same among treatment types. Targeted therapy predicted for less depression (p=.028) and small cell lung cancer predicted for more depression (p=.041) when controlling for age and sex however these predictors were not significant when controlled for inflammation.

Conclusion—New immunotherapy and targeted therapies are associated with less depression and inflammation among patients who are living longer while their physical symptoms are the same.

1. Introduction

1.1 Variables contributing to psychological outcomes in the lung cancer setting

Historically, metastatic lung cancer is known for its high rates of comorbid depression and other psychological associations as well as a high degree of related physical symptomatology.^{1,2} For example, dyspnea, cachexia, and pain may be the result of

Contact Information: Daniel C. McFarland, DO, Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center, 641 Lexington Ave, New York, NY 10022, danielcurtismcfarland@gmail.com, Tel#. 646-888-0026, Fax#. 646-227-7283.

Conflict of Interests: No conflict of interest reported by authors

progressive disease, sequelae of lung cancer such as pulmonary venothrombosis, or even from the lung cancer treatment itself causing anemia and anorexia. Distress, anxiety, and depression in the setting of metastatic lung cancer are exacerbated by progressive disability, loss of independence, unrelenting physical symptoms such as pain, or underlying mechanistic reasons such as systemic inflammation.^{3–5} The prevalence of depression in lung cancer (16–29%)^{6,7} exceeds the standard prevalence of major depression in cancer more generally, which is approximately 15%.² Distress and anxiety may also result from similar associations and are more closely attached to dyspnea and pain, for example.⁸ Unfortunately, these physical and psychological symptoms (e.g., dyspnea and anxiety) co-exist in patients whose cancers, like lung cancer, have the poorest survival rate.⁹

Systemic treatments affect all of these variables while additionally contributing to a variable side effect profile. However, paradigmatic shifts in systemic treatments for lung cancer have taken place over the last decade.^{10,11} Ten years ago, limited targeted therapy drugs were available, such as the antiangiogenesis inhibitor, bevacizumab, and the Epidermal Growth Factor Receptor (EGFR) inhibitors erlotinib and gefitinib, but the vast majority of patients were treated with chemotherapy only.¹² Today, there are three primary classes of drugs for the treatment of systemic lung cancer: many forms of small molecule targeted therapies, immunotherapies, and traditional cytotoxic chemotherapies.¹³

Understanding the psychological effects of the major classes of systemic lung cancer treatments is important since the rate of depression, in particular, is already elevated and leads to worse overall survival among those patients with depression.¹⁴ Encouragingly, appropriately addressing and treating depression in the cancer setting restore survival to its baseline without depression.¹⁴ Psychosocial resources are limited in most cancer treatment settings.¹⁵ Therefore, it is helpful to know which patients are at a higher risk of psychological or psychiatric co-morbidity in order to best triage patient and allocate resources. This information will be helpful for psychiatric consultants who are evaluating patients with lung cancer and liaising with oncologic clinicians.

1.2 Targeted Therapies

Targeted therapies have emerged as a result of understanding the interplay of ‘driver’ mutations and their susceptibilities to small molecule drugs that work intracellularly (within the cancer cell) or on the cell surface.¹⁶ Standard of practice has resulted in a proliferation of accepted ‘targetable’ mutations for which we have appropriate therapies.¹⁷ These treatments have grown from small molecule inhibitors that treat mutations in the EGFR gene (~20%) and the Anaplastic lymphoma kinase (ALK) gene (~4%) to an array of possible driver mutations (e.g., BRAF, HER2, NTRK, ROS1) thanks to advances in molecular testing.¹⁸ Now, molecular testing has become accepted practice and targetable mutations are identified and incorporated into standard treatments primarily for non-small cell lung cancer (NSCLC).¹⁹ These drugs come in oral form and are generally well tolerated with expected side effects which are most commonly rash, diarrhea, and fatigue.²⁰ These side effects may be responsive to dose reductions as well. These small molecule inhibitors can cause thyroid dysfunction and generally are effective at crossing the blood brain barrier to treat brain lesions. Despite their therapeutic efficacy on lung cancers, their actual associations with

psychological/psychiatric phenomena are not fully appreciated. While not every patient experiences predictable side effects, they can be severe and interfere with quality of life significantly, which would have distinct ramifications for psychological wellbeing.

1.3 Immunotherapy

The next newest class is immunotherapy.²¹ Different forms of immunotherapy have been used to treat various cancers such as Interleukin-2 (IL-2) for the treatment of melanoma or Bacillus Calmette-Guerin (BCG) vaccine in the treatment of superficial bladder cancers. However, these are older forms of immunotherapy that manipulate the innate immune system to elicit a general inflammatory response. New, more elegantly designed 'immunotherapy' treatments are known as 'checkpoint inhibitors' since they inhibit certain checkpoints in the inflammatory cascade that tell the adaptive immune system to stop proliferating.²² These checkpoint inhibitors work by stopping the inherent inhibition of the immune system that normally protects the body from excessive inflammation or from developing autoimmune type of physiology or disease, in other words. It acts by taking the brakes off the immune system and inducing an autoimmune-like state relying on an immune response directed at the cancer. Checkpoint inhibitors are monoclonal antibodies directed at specific sites on the surface of inflammatory cells such as T lymphocytes called Program Cell Death Protein 1 (PD-1), or directed to the surface of other inflammatory cells (e.g., macrophages) called Programmed Death-ligand 1 (PDL-1) or on the surface of regulatory T cells called Cytotoxic T-Lymphocyte-associated Protein 4 (CTLA-4) that signal for the immune system to turn itself off when activated by a cancer cell and actually turn the immune system on when inhibited by one of these checkpoint inhibitors. In the lung cancer setting, the PD-1 (nivolumab, pembrolizumab) and PDL-1 (atezolizumab, avelumab, durvalumab) checkpoint inhibitors were used as second line treatment but could be used as a first line treatment if the cancer cells expression of PD-L1 protein was high because this infers a higher response rate to immunotherapy over traditional chemotherapy. In 2017, immunotherapy was approved to be used with chemotherapy as a first line treatment. In addition, the PD-1 inhibitor, nivolumab is used in combination with another class of checkpoint inhibitor called CTLA-4 inhibitor (e.g., ipilumab) with small cell lung cancer. This combination allows for an increased immune response. Surprisingly the overall response rate is not typically that much better than chemotherapy but the magic of immunotherapy is in the duration of response which can be for years once a response is obtained. It is also thought to change the trajectory of disease even if the disease does not become appreciably smaller (stable disease). Side effects are not predictable, but mimic autoimmune disease and most commonly cause fatigue, diarrhea, rash, thyroid dysfunction.

1.4 Chemotherapy

Chemotherapies are drugs that are directly toxic to the cancer DNA and take advantage of the fact that cancer cells are exposing their DNA by dividing faster than normal healthy cells. They incur side effects by indiscriminate killing of replicating cells (healthy or cancerous). Most patients will be exposed to chemotherapy at some point in their treatment trajectory.²³ Side effects from chemotherapy are more predictable generally with higher prevalence of fatigue, diarrhea, neuropathy, and cytopenias, for example.²⁴

1.5 Possible psychological associations with lung cancer-related physical symptoms and inflammation

While these broad categories of anticancer treatments may differentially influence psychological wellbeing, the effects may be a consequence of physical symptoms or treatment or cancer-related inflammation.^{25,26} Both physical symptoms and cancer-related inflammation are responsible for excessive amount of depression and other psychological symptoms seen in patients with lung cancer.²⁷ Inflammation has been associated with depression in multiple clinical settings including medically healthy and chronically ill patients, but is particularly relevant for lung cancer where there are high rates of both depression and inflammation are associated with worse survival outcomes.^{28–30} Inflammation may play a role in treatment refractory depression as well.^{31,32} Peripheral biomarkers of inflammation are being studied in population-based and case controlled studies.^{33–38} However, the role of systemic lung cancer therapies, including new therapies like targeted therapy and immunotherapy, in influencing inflammation and depression has not been studied previously.

C-reactive protein (CRP) is an acute phase reactant and biomarker produced by the liver in response to multiple pro-inflammatory cytokines, especially IL-6, and increases by at least 25% with general inflammation.^{39,40} Peripheral blood CRP has also recently been shown to correlate strongly with central (cerebrospinal fluid) CRP, which is in turn correlated with inflammatory markers in the CSF.⁴¹ Albumin is the most common protein in the blood. It is produced by the liver and it decreases as a negative acute phase reactant in response to inflammation, similar to CRP and other acute phase reactants.⁴² Albumin has been associated with depression in limited settings (e.g., with HIV) and has been studied most as a prognostic marker of survival in cancer settings.^{43–45} CRP and albumin have long half-lives and therefore less diurnal/circadian fluctuation and provide a good measure of general inflammation that may correspond with total number or individual physical symptoms. Neutrophil to Lymphocyte Ratio (NLR) is another marker of general inflammation that measures both the innate (neutrophil) and adaptive (lymphocyte) forms of the immune system.^{46,47} NLR has been used as a prognostic marker in lung cancer as well and is also helpful in this setting because is a very broad measure of lymphocyte activity which can decrease in the setting of depression and may be relevant for those patients receiving immunotherapy (i.e., checkpoint therapy inhibits T regulatory cells).^{48,49}

Given that targeted therapy and immunotherapy are relatively new drugs with variable side effect profiles, their associations with psychological symptoms have not been fully appreciated. We hypothesize that the predictability and higher percentage of physical symptoms and inflammation associated with the cell destruction of chemotherapy will create higher levels of psychological outcomes, specifically depression, in patients with metastatic lung cancer receiving chemotherapy over other systemic drugs such as targeted therapies and immunotherapy.

2. Methods

The Memorial Sloan Kettering Cancer Center Institutional Review Board (IRB) approved this study May 2018. Surveys and routine blood work (CRP, albumin, NLR) were collected as standard of care practice from May 2017 to November 2017.

2.1 Participants

Men and women with histologically confirmed stage IV lung cancer who were undergoing active treatment, spoke English, and had a performance status of ECOG 2 or greater were included. Participants with other cancers or not undergoing treatment for stage IV lung cancer were excluded. Participants had to be on active treatment for at least one month and had to be more than one month from receiving the diagnosis of lung cancer to be included.

2.2 Procedure

Patients were asked to complete a one-time survey by a treating staff member (e.g., nurse practitioner, medical oncologist). They filled out the questionnaire containing standardized survey questions, and laboratory values (CRP, albumin, NLR) were obtained the same day that the questionnaires were completed. Available psychological services were provided in the survey, and patients were asked to raise any concerns with clinic staff and, in particular, to tell a staff member if they felt significantly depressed or had suicidal ideation. The surveys were collected as routine standard of care screening as per distress screening guidelines.

3. Materials

3.1 Patient demographic and medical characteristics

Patient demographic information was obtained from the medical record and included age, race/ethnicity, sex, marital status, body mass index (BMI), length of time since diagnosis, type of treatment (e.g., chemotherapy, immunotherapy, targeted therapy), line of treatment (i.e., 1st, 2nd, 3rd or beyond), and whether they were taking an antidepressant medication.

3.2 Biological Characteristics of inflammation

A CRP value was obtained by turbidimetric immunoassay in a Clinical Laboratory Improvement Amendments (CLIA) certified lab.⁵⁰ Inter- and intra-assay coefficient of variation is reliably less than 5%. A CRP > 1 mg/ml has been used in studies to identify patients with generalized inflammation and to evaluate preferential antidepressant responses.^{51,52} A cut-point of CRP >3mg/ml reveals dopamine depletion on fMRI.³⁴ An albumin bromoresol green (BCG) assay is used for the quantification of albumin in human serum or plasma.⁵³ Standard laboratory procedures were used to obtain neutrophil and lymphocyte values from the standard complete blood counts in the clinical lab at MSKCC.

3.3 Distress and Associated Self-Reported Problems

The Distress Thermometer and Problem List (DT&PL) is a one-item measure of distress, ranging from 0 (Not at all distressed) to 10 (Extremely distressed). A cut-off of 4 has been accepted by the National Comprehensive Cancer Network to indicate clinically meaningful

distress.⁵⁴ The DT&PL has been validated among international cancer populations.⁵⁵ Problem list categories include Practical (0–6), Familial (0–4), Emotional (0–6), Spiritual (0–1), and Physical Problems (0–22).

3.4 Anxiety and Depression

Anxiety and depression severity was measured by the Hospital Anxiety and Depression scale (HADS), which has been validated in the lung cancer setting.^{56,57} The HADS is a 14-item symptom rating scale that was developed to identify clinically significant cases of anxiety and depressive disorders among medically ill patients.⁵⁶ Unlike most symptom rating scales, physical symptoms are excluded from the HADS due to the potential confounding effects of illness on symptoms such as sleep, appetite disturbance, and fatigue. The HADS is divided into an anxiety subscale (HADS-A) and a depression subscale (HADS-D). Responses are rated 0 to 3 points such that total scores on the HADS-A and HADS-D may range from 0 to 21 points. A cut-off of 8 on the HADS-A and HADS-D subscales is most commonly used to identify clinically significant depression, with an average sensitivity and specificity of 0.80.^{56,58}

4. Statistical Analysis

The primary outcome of this study is the psychological outcomes associated with the three primary types of systemic anticancer treatments in patients with metastatic lung cancer. Secondly, this study will assess their associations with markers of systemic inflammation, physical symptoms, and other demographic and treatment related variables. Because CRP and NLR data are not normally distributed (see below), CRP and NLR values were log transformed prior to data analysis; however, untransformed values are also reported for ease of interpretation. Univariate associations between patient demographic (age, BMI, time with disease), inflammatory (CRP, albumin, NLR) and psychological characteristics (distress, anxiety, depression) and treatment type (chemotherapy, immunotherapy, and targeted therapy) were assessed using ANOVA. Categorical variables (line of treatment, disease type, race, sex, married/partnered status, antidepressant use) were evaluated for their association with treatment type using chi square analyses. Univariate associations between continuous variables and depression were assessed using rank-order correlations for age, BMI, time since diagnosis, CRP, albumin, NLR, and ANOVAs were used for ordinal variables (line of treatment, treatment type, and disease type) and categorical variables (type of treatment, disease status). Statistically significant covariates were selected for inclusion in multiple regression analysis. For multi-level categorical variables, dummy-coding was used to assess the contribution of treatment type (i.e., immunotherapy and targeted therapies; chemotherapy was set as the reference variable) and disease type (i.e., squamous cell and small cell lung cancer; adenocarcinoma was set as the reference variable). Statistical procedures were performed using the SPSS version 24 software (SPSS, Chicago, IL 2013), and all statistical tests were two-tailed with a 5% significance level.

5. Results

Out of 140 potential participants, 109 returned survey information (77.9% response rate). Sample characteristics are presented in Table 1. The average age was 65.9 years old and the

majority of the sample was female (62.4%), white (85.2%), and married (69.7%). Most patients had adenocarcinoma non-small cell lung cancer (71.8%), followed by small cell lung cancer (16.5%) and squamous cell carcinoma (6.4%) and 4.6% were unspecified type of lung cancer. Forty-seven participants were receiving chemotherapy (45.2%), 35 were receiving immunotherapy (33.7%), 22 were receiving targeted therapies (21.2%), and 6 were on a treatment that didn't fit into one of the three main categories (5.5%). The majority of participants were in the 1st line of treatment (53.3%), followed by 2nd line (32.4%), and 3rd line and beyond treatments (14.3%), and 4.5% were not on known treatments.

Patients had their lung cancer for an average of 15.4 months and had an average of 2.19 emotional problems (from 0 to 6 possible) and 4.8 physical problems (from 0 to 22 possible) among other issues listed in Table 1. Twenty-six of the 109 participants endorsed clinically significant symptoms of depression (HADS-D 8) (23.9%) while 26 endorsed clinically significant anxiety (HADS-A 8) (23.9%), and 39 endorsed clinically significant distress (DT&PL 4) (41.1%). Eighteen participants reported that they were taking antidepressant medication (16.5%), including only seven out of the 26 participants with clinically significant depression (26.9%).

Inflammatory indices included a mean CRP concentration of 1.79 mg/L (SD 2.5; Median 0.75 mg/L) with a range of <0.05 to 18.51 mg/L. As expected, CRP values were highly skewed and kurtotic (skew=2.45, kurtosis=6.78); the distribution approximated a normal distribution following log transformation (skew=-0.78, kurtosis=0.85). The average albumin was 3.81 g/dL (SD .37) (range 2.8–4.6 g/dL) and NLR was 6.04 (SD 5.28) (range .68–24.3). Participants reported an average of 4.8 (SD 3.46) physical problems with a range of 0 to 15 (max is 22). While number of physical symptoms was highly correlated to distress ($r=.342$, $p=.001$), anxiety ($r=.452$, $p<.001$), and depression ($r=.625$, $p<.001$), number of physical symptoms was not significantly different between chemotherapy (5.1 [SD 4.0]), immunotherapy (4.9 [SD 3.6]), and targeted therapy (4.4 [SD 3.5]) ($F=.249$, $p=.780$).

Table 2 demonstrates that chemotherapy was associated with greater levels of depression (HADS-D 6.00) than immunotherapy (HADS-D 4.9) or targeted therapy (HADS-D 2.91) ($P=.006$) and higher CRP levels (2.45 mg/L) than immunotherapy (CRP 1.73 mg/L) or targeted therapy (CRP .33 mg/L). At the same time, NLR was higher in immunotherapy (NLR 7.48) versus chemotherapy (NLR 6.15) or targeted therapy (NLR 3.58). The elevated NLR in the immunotherapy group is based on the higher neutrophil counts in the chemotherapy group ($5.4 \times 10^9/L$) and immunotherapy group ($6.2 \times 10^9/L$) over the targeted therapy group ($3.6 \times 10^9/L$) ($F= 3.499$, $p=.034$) because the lymphocyte counts did not vary across groups ($F=.567$, $p=.569$). Albumin did not vary significantly between treatment types ($p=.34$). Length of time with disease was shorter in the chemotherapy group (8.91 months) and significantly longer in the immunotherapy group (17.29 months) and targeted therapy group (23.23 months) ($F= 6.465$, $p=.002$).

There is an uneven distribution of treatment types (chemotherapy, immunotherapy, and targeted therapy) among line of treatment ($p<.001$) with a greater amount of immunotherapy in the second line and disease type ($p=.032$) and targeted therapies only being used on adenocarcinoma NSCLC (Table 2).

In addition to treatment type, other significant associations with depression (HADS-D) include disease type and inflammatory markers. A greater amount of depression was seen in patients with small cell lung cancer (HADS-D 6.72) over adenocarcinoma NSCLC (HADS-D 4.32) and squamous cell NSCLC (HADS-D 5.71). Depression was also associated with inflammatory markers CRP ($r=.47$, $p<.001$), albumin ($r=-.35$, $p<.001$), and NLR ($r=.2$, $p=.047$) (Table 3).

Multivariate analyses evaluating predictors of depression (Table 4) found that targeted therapy predicted less depression ($p=.028$) and small cell lung cancer predicted for more depression ($p=.041$) when controlling for age and sex but that these predictors were not significant when controlling for inflammatory markers (CRP, albumin, and NLR). CRP predicts for depression when taking into account age and sex control variables, treatment and disease types, and other inflammatory markers.

6. Discussion

New systemic treatment options for patients with lung cancer, targeted therapies and immunotherapy, are associated with less depression and also with less inflammation, but there were no differences for levels of distress or anxiety. While a multivariate analysis revealed that treatment type was associated with depression, the association was not significant when controlling for inflammation. Inflammation may be mediating the relationship between treatment type and depression. The rates of distress, anxiety, and depression seemed to be consistent with historical rates. Also, the distribution of systemic treatment types is also consistent with what would be expected in a cohort of stage IV lung cancer that included both NSCLC and small cell lung cancer types.

The relationship between chemotherapy and depression may be due to cell lyses causing inflammation versus other potential depression-causing mechanisms. Patients receiving chemotherapy had lung cancer for a shorter period of time. Although the majority of chemotherapy was given in the 1st line setting, receiving chemotherapy may also correspond with more advanced or aggressive disease or disease and patient medical situations in which immunotherapy or targeted therapies could not be offered. In other words, patients receiving chemotherapy may have actually been closer to the end of life since their diseases were more advanced or treatment options were more limited and advanced disease was responsible for greater depression rates. However, the number of physical symptoms reported was the same between each treatment group. Although physical symptoms and depression are related in many clinical scenarios, this finding suggests that the difference in rates of depression between treatment groups was independent of physical symptoms and therefore would not be responsible for greater depression in the chemotherapy group.

Immunotherapy and targeted therapies incurred as many physical symptoms as chemotherapy. This is consistent with the notion that these therapies are also associated with significant physical symptom side effects even though they are generally thought of as more tolerable.⁵⁹ It is possible that although the number of physical symptoms were similar that the severity was less, for example.

6.1 Limitations

This observational study was limited by the number of observations at a single institution and therefore would need to be repeated in order to be verified. This study was cross-sectional at a cancer referral center. Therefore, the average age was about 6 years younger than the average patient with lung cancer and also adenocarcinoma was more heavily represented as these patients may have been seeking novel treatment options. Symptom trajectories during different treatments (chemotherapy, targeted therapies and immunotherapy) would be helpful to understand psychological associations with these three main treatment types. Also, the study only evaluated a limited number of possible mechanisms to explain psychological associations. For example, a future study could account for the effect of socioeconomic status (SES) on the psychological association of treatment types since SES is known to effect cancer outcomes.⁶⁰ Smoking status was not available but is also associated with psychological outcomes and should be controlled for, especially because there is a complicated relationship between smoking, inflammation and immunotherapy.⁶¹ Another limitation is that while these treatment categories are not going to change, many treatments in these categories will continue to develop and evolve into combinations for example, which have already come into use. This complicates the simple categorical division of treatment options presented in this study.

6.2 Implications for Consult-Liaison Psychiatry

Historically, lung cancer has been a cancer type that has many physical and emotional symptoms and patient face end of life issues quickly in their disease trajectory. These new treatments have changed the landscape of lung cancer over the last decade such that there is a more varied clinical presentation among patients with stage IV lung cancer. This means that while certain subsets of patients, perhaps receiving targeted and/or immunotherapy, may be able to maintain a good quality of life or even thrive under the diagnosis of lung cancer, other patients continue to have greater symptom difficulties, like depression, that require a greater amount of attention and care. This study highlights some of these differences in patient profiles as determined by their current treatment types. While these are clearly generalizations, understanding the relationship between lung cancer treatment type and psychological variables can help the consulting psychiatrist to conceptualize the patient trajectory and risk of developing depression, for example. This information may also help determine allocation of resources that may translate into frequency of follow up visits, coordinated care, etc.. Also, the study highlights how quickly paradigmatic shifts in treatment can fundamentally change the symptomatic care required for groups of patients. It would be interesting to follow these patients longitudinally in order to understand if there are other treatment-specific psychological outcomes that develop in patients taking targeted and immunotherapies over time.

6.3 Future Directions

This study is hypothesis-generating but the findings warrant a further and deeper evaluation into the difference in psychological symptoms in patients with lung and other cancers based on new paradigmatic shifts in anti-cancer treatments. Future studies should evaluate these symptoms in a longitudinal manner, with a greater number of participants. Inflammatory

markers should be measured over time and evaluated for mediation/moderation of psychological symptoms. The specific relationship between chemotherapy and depression should be further explored. These differences in depression among treatment types may translate into targeted psychological treatments for depression in the setting of chemotherapy, for example.

6.4 Summary

This study highlights the interplay between treatment type, which is really a life altering event, and psychological states while trying to understand what may be responsible for the differences. Chemotherapy is associated with depression and greater inflammation than either immunotherapy or targeted therapies. Targeted therapy and immunotherapy are associated with longer life span and may offer a reprieve from depressive symptoms in patients with metastatic lung cancer.

References

1. Krebber AM, Buffart LM, Kleijn G, et al. Prevalence of depression in cancer patients: a meta-analysis of diagnostic interviews and self-report instruments. *Psycho-oncology*. 2014;23(2):121–130. [PubMed: 24105788]
2. Mitchell AJ, Chan M, Bhatti H, et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. *The Lancet. Oncology*. 2011;12(2):160–174. [PubMed: 21251875]
3. Kurtz ME, Kurtz JC, Stommel M, Given CW, Given B. Predictors of depressive symptomatology of geriatric patients with lung cancer—a longitudinal analysis. *Psycho-oncology*. Jan-Feb 2002;11(1):12–22. [PubMed: 11835589]
4. Graves KD, Arnold SM, Love CL, Kirsh KL, Moore PG, Passik SD. Distress screening in a multidisciplinary lung cancer clinic: prevalence and predictors of clinically significant distress. *Lung cancer*. 2007;55(2):215–224. [PubMed: 17084483]
5. Du YJ, Zhang HY, Li B, et al. Sputum interleukin-6, tumor necrosis factor-alpha and Salivary cortisol as new biomarkers of depression in lung cancer patients. *Progress in neuropsychopharmacology & biological psychiatry*. 2013;47:69–76.
6. Hopwood P, Stephens RJ. Depression in patients with lung cancer: prevalence and risk factors derived from quality-of-life data. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 2000;18(4):893–903. [PubMed: 10673533]
7. Walker MS, Zona DM, Fisher EB. Depressive symptoms after lung cancer surgery: Their relation to coping style and social support. *Psycho-oncology*. 2006;15(8):684–693. [PubMed: 16302291]
8. Brintzenhofe-Szoc KM, Levin TT, Li Y, Kissane DW, Zabora JR. Mixed anxiety/depression symptoms in a large cancer cohort: prevalence by cancer type. *Psychosomatics*. Jul-Aug 2009;50(4):383–391. [PubMed: 19687179]
9. Pirl WF, Temel JS, Billings A, et al. Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study. *Psychosomatics*. May-Jun 2008;49(3):218–224. [PubMed: 18448776]
10. Toschi L, Rossi S, Finocchiaro G, Santoro A. Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. *Ecancermedicalscience*. 2017;11:787. [PubMed: 29225694]
11. Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. *Lancet*. 2017;389(10066):299–311. [PubMed: 27574741]
12. Wakelee H, Kelly K, Edelman MJ. 50 Years of progress in the systemic therapy of non-small cell lung cancer. *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Meeting 2014*:177–189.

13. Hanna N, Johnson D, Temin S, et al. Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 10 20 2017;35(30):3484–3515. [PubMed: 28806116]
14. Sullivan DR, Forsberg CW, Ganzini L, et al. Longitudinal Changes in Depression Symptoms and Survival Among Patients With Lung Cancer: A National Cohort Assessment. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 11 20 2016;34(33):3984–3991. [PubMed: 27996350]
15. Butow PN, Phillips F, Schweder J, et al. Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. *Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer* 1 2012;20(1):1–22.
16. Hoelder S, Clarke PA, Workman P. Discovery of small molecule cancer drugs: successes, challenges and opportunities. *Molecular oncology*. 4 2012;6(2):155–176. [PubMed: 22440008]
17. Barlesi F, Mazieres J, Merlio JP, et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). *Lancet*. 4 2 2016;387(10026):1415–1426. [PubMed: 26777916]
18. Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. *Jama*. 5 21 2014;311(19):1998–2006. [PubMed: 24846037]
19. Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. 11 10 2014;32(32):3673–3679. [PubMed: 25311215]
20. Silva AP, Coelho PV, Anazetti M, Simioni PU. Targeted therapies for the treatment of non-small-cell lung cancer: Monoclonal antibodies and biological inhibitors. *Human vaccines & immunotherapeutics*. 4 3 2017;13(4):843–853. [PubMed: 27831000]
21. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. *Translational lung cancer research*. 4 2017;6(2):196–211. [PubMed: 28529902]
22. Ellis PM, Vella ET, Ung YC. Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. *Clinical lung cancer*. 9 2017;18(5):444–459 e441. [PubMed: 28416123]
23. Fennell DA, Summers Y, Cadranel J, et al. Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. *Cancer treatment reviews*. 3 2016;44:42–50. [PubMed: 26866673]
24. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. *Journal of the National Cancer Institute*. 3 5 2003;95(5):362–372. [PubMed: 12618501]
25. Tuck NL, Grant RC, Jackson A, Brooks AE, Considine NS. Beyond Self-Report: Performance Measures of Emotional Competencies Predict Symptoms of Depression and Anxiety, Physical Symptoms, Self-Rated Health, and Immunoregulatory Molecules. *Annals of behavioral medicine : a publication of the Society of Behavioral Medicine*. 12 2016;50(6):823–835. [PubMed: 27325315]
26. Quist M, Adamsen L, Rorth M, Laursen JH, Christensen KB, Langer SW. The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy. *Integrative cancer therapies*. 7 2015;14(4):341–349. [PubMed: 25800229]
27. Brown DJ, McMillan DC, Milroy R. The correlation between fatigue, physical function, the systemic inflammatory response, and psychological distress in patients with advanced lung cancer. *Cancer*. 1 15 2005;103(2):377–382. [PubMed: 15558809]
28. Valkanova V, Ebmeier KP, Allan CL. CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. *Journal of affective disorders*. 9 25 2013;150(3):736–744. [PubMed: 23870425]

29. Smith KJ, Au B, Ollis L, Schmitz N. The association between C-reactive protein, Interleukin-6 and depression among older adults in the community: A systematic review and meta-analysis. *Experimental gerontology*. 2 2018;102:109–132. [PubMed: 29237576]
30. Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivimäki M. Cumulative meta-analysis of interleukins 6 and 1beta, tumour necrosis factor alpha and C-reactive protein in patients with major depressive disorder. *Brain, behavior, and immunity*. 10 2015;49:206–215.
31. Watson J, Round A, Hamilton W. Raised inflammatory markers. *Bmj*. 2 03 2012;344:e454. [PubMed: 22306478]
32. Strawbridge R, Arnone D, Danese A, Papadopoulos A, Herane Vives A, Cleare AJ. Inflammation and clinical response to treatment in depression: A meta-analysis. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology*. 10 2015;25(10):1532–1543. [PubMed: 26169573]
33. Smith RS. The macrophage theory of depression. *Medical hypotheses*. 8 1991;35(4):298–306. [PubMed: 1943879]
34. Felger JC, Li Z, Haroon E, et al. Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. *Molecular psychiatry*. 10 2016;21(10):1358–1365. [PubMed: 26552591]
35. Maes M, Bosmans E, De Jongh R, Kenis G, Vandoelaeghe E, Neels H. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. *Cytokine*. 11 1997;9(11):853–858. [PubMed: 9367546]
36. Hauser P, Khosla J, Aurora H, et al. A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. *Molecular psychiatry*. 2002;7(9):942–947. [PubMed: 12399946]
37. Bonaccorso S, Marino V, Biondi M, Grimaldi F, Ippoliti F, Maes M. Depression induced by treatment with interferon-alpha in patients affected by hepatitis C virus. *Journal of affective disorders*. 12 2002;72(3):237–241. [PubMed: 12450640]
38. Capuron L, Hauser P, Hinze-Selch D, Miller AH, Neveu PJ. Treatment of cytokine-induced depression. *Brain, behavior, and immunity*. 10 2002;16(5):575–580.
39. Moshage HJ, Janssen JA, Franssen JH, Hafkenscheid JC, Yap SH. Study of the molecular mechanism of decreased liver synthesis of albumin in inflammation. *The Journal of clinical investigation*. 6 1987;79(6):1635–1641. [PubMed: 3584463]
40. Steel DM, Whitehead AS. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. *Immunology today*. 2 1994;15(2):81–88. [PubMed: 8155266]
41. Felger JC, Haroon E, Patel TA, et al. What does plasma CRP tell us about peripheral and central inflammation in depression? *Molecular psychiatry*. 6 12 2018.
42. Green MD. Acute Phase Responses to Novel, Investigational Vaccines in Toxicology Studies: The Relationship Between C-Reactive Protein and Other Acute Phase Proteins. *International journal of toxicology*. Sep-Oct 2015;34(5):379–383. [PubMed: 26268767]
43. Poudel-Tandukar K, Jacelon CS, Bertone-Johnson ER, Palmer PH, Poudel KC. Serum albumin levels and depression in people living with Human Immunodeficiency Virus infection: a cross-sectional study. *Journal of psychosomatic research*. 10 2017;101:38–43. [PubMed: 28867422]
44. Pascoe MC, Skoog I, Blomstrand C, Linden T. Albumin and depression in elderly stroke survivors: An observational cohort study. *Psychiatry research*. 12 15 2015;230(2):658–663. [PubMed: 26520562]
45. Lv GY, An L, Sun XD, Hu YL, Sun DW. Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: a meta-analysis. *Clinica chimica acta; international journal of clinical chemistry*. 1 2018;476:81–91. [PubMed: 29170102]
46. Euteneuer F, Dannehl K, Del Rey A, Engler H, Schedlowski M, Rief W. Peripheral Immune Alterations in Major Depression: The Role of Subtypes and Pathogenetic Characteristics. *Frontiers in psychiatry*. 2017;8:250. [PubMed: 29218020]
47. Aydin Sunbul E, Sunbul M, Yanartas O, et al. Increased Neutrophil/Lymphocyte Ratio in Patients with Depression is Correlated with the Severity of Depression and Cardiovascular Risk Factors. *Psychiatry investigation*. 1 2016;13(1):121–126. [PubMed: 26766954]

48. Yin Y, Wang J, Wang X, et al. Prognostic value of the neutrophil to lymphocyte ratio in lung cancer: A meta-analysis. *Clinics*. 7 2015;70(7):524–530. [PubMed: 26222823]
49. Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung cancer*. 9 2017;111:176–181. [PubMed: 28838390]
50. Pineiro M, Pato R, Soler L, et al. A new automated turbidimetric immunoassay for the measurement of canine C-reactive protein. *Veterinary clinical pathology*. 3 2018;47(1):130–137. [PubMed: 29377276]
51. Jha MK, Minhajuddin A, Gadad BS, et al. Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial. *Psychoneuroendocrinology*. 4 2017;78:105–113. [PubMed: 28187400]
52. Uher R, Tansey KE, Dew T, et al. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline. *The American journal of psychiatry*. 12 01 2014;171(12):1278–1286. [PubMed: 25017001]
53. Coley-Grant D, Herbert M, Cornes MP, Barlow IM, Ford C, Gama R. The impact of change in albumin assay on reference intervals, prevalence of 'hypoalbuminaemia' and albumin prescriptions. *Annals of clinical biochemistry*. 1 2016;53(Pt 1):112–116. [PubMed: 26195486]
54. Holland JC, Bultz BD, National comprehensive Cancer N. The NCCN guideline for distress management: a case for making distress the sixth vital sign. *Journal of the National Comprehensive Cancer Network : JNCCN*. 1 2007;5(1):3–7. [PubMed: 17323529]
55. Donovan KA, Grassi L, McGinty HL, Jacobsen PB. Validation of the distress thermometer worldwide: state of the science. *Psycho-oncology*. 3 2014;23(3):241–250. [PubMed: 25160838]
56. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. *Journal of psychosomatic research*. 2 2002;52(2):69–77. [PubMed: 11832252]
57. Schellekens MPJ, van den Hurk DGM, Prins JB, Molema J, van der Drift MA, Speckens AEM. The suitability of the Hospital Anxiety and Depression Scale, Distress Thermometer and other instruments to screen for psychiatric disorders in both lung cancer patients and their partners. *Journal of affective disorders*. 10 2016;203:176–183. [PubMed: 27295374]
58. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. *Acta Psychiatr Scand*. 6 1983;67(6):361–370. [PubMed: 6880820]
59. Sgambato A, Casaluce F, Sacco PC, et al. Anti PD-1 and PDL-1 Immunotherapy in the Treatment of Advanced Non- Small Cell Lung Cancer (NSCLC): A Review on Toxicity Profile and its Management. *Current drug safety*. 2016;11(1):62–68. [PubMed: 26412670]
60. Sullivan DR, Forsberg CW, Ganzini L, et al. Depression symptom trends and health domains among lung cancer patients in the CanCORS study. *Lung cancer*. 10 2016;100:102–109. [PubMed: 27597288]
61. Oya Y, Yoshida T, Kuroda H, et al. Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer. *Oncotarget*. 11 28 2017;8(61):103117–103128. [PubMed: 29262550]

Table 1:

Clinical and Demographic Characteristics of the Sample

	Total (n=109)
	<i>M (SD)</i>
Age (years)	65.9 (9.3)
Body Mass Index	26.1 (5.0)
Time with Disease (months)	15.4 (17.3)
C Reactive Protein (mg/ml)	1.79 (2.5)
Albumin (2.8–4.6)	3.81 (.377)
NLR (0.68–24.33)	6.04 (5.27)
Depression Score (HADS-D) (0–21)	4.9 (3.7)
Anxiety (HADS-A) (0–21)	5.39 (3.94)
Distress (0–10)	3.91 (2.96)
Practical Problems (0–3)	.38 (.63)
Familial Problems (0–3)	.22 (.56)
Emotional Problems (0–6)	2.19 (2.02)
Spiritual Problems (0–1)	.04 (.19)
Physical Problems (0–15)	4.8 (3.46)
	N (%)
Meets Criteria Screen	
• Depression (HADS-D 8)	26 (23.6%)
• Anxiety (HADS-A 8)	26 (23.6%)
• Distress (DT&PL 4)	39 (41.1%)
Gender	
• Male	41 (37.6%)
• Female	68 (62.4%)
Disease Type	
• Adenocarcinoma	79 (71.8%)
• Squamous cell carcinoma	7 (6.4%)
• Small Cell Lung Cancer	18 (16.5%)
• Unspecified	5 (4.6%)
Treatment Type	
• Chemotherapy	47 (45.2%)
• Immunotherapy	35 (33.7%)
• Targeted Therapy	22 (21.2%)
• Missing	6 (5.5%)
Line of Treatment	
• 1 st	56 (53.3%)
• 2 nd	34 (32.4%)

	Total (n=109)
	<i>M (SD)</i>
• 3 rd or beyond	15 (14.3%)
• Missing	5 (4.5%)
Race/Ethnicity	
• Black	7 (6.4%)
• White	93 (85.2%)
• Latino	7 (6.4%)
• Asian	2 (1.8%)
Married	
• Yes	76 (69.7%)
• No	33 (30.3%)
Antidepressant	
• Yes	18 (16.5%)
• No	91 (83.5%)

Table 2:

Univariate analysis of demographic and disease characteristics and treatment type.

	<i>chemo</i>	<i>immuno</i>	<i>targeted</i>	<i>F</i>	<i>P</i>
Age	-	-	-	.53	.59
BMI	-	-	-	.32	.73
Time with Disease (months)	8.9 (11.4)	17.3 (12.9)	23.2 (26.6)	6.465	.002
CRP (mg/L)	2.45 (3.3)	1.73 (1.7)	0.3 (0.3)	9.332	<.001
Albumin (g/dL)	-	-	-	1.078	.34
NLR	6.2 (5.2)	7.5 (6.1)	3.6 (3.3)	3.431	.036
Distress (DT&PL)	-	-	-	2.976	.06
Practical Problems	-	-	-	.064	.938
Family Problems	0.2 (0.5)	0.1 (0.3)	0.5 (0.9)	4.425	.015
Emotional Problems	-	-	-	2.126	.125
Spiritual Problems	-	-	-	.212	.809
Physical Problems	-	-	-	.249	.780
Anxiety (HADS-A)	-	-	-	1.539	.22
Depression (HADS-D)	6.0 (3.7)	4.9 (3.7)	2.9 (3.3)	5.425	.006
	<i>chemo</i>	<i>immuno</i>	<i>targeted</i>	χ^2	<i>p</i>
Line of Treatment				26.124	<.001
1 st	36	9	11		
2 nd	4	20	7		
3 rd and beyond	6	5	4		
Disease Type				10.548	.032
Adenocarcinoma	29	26	22		
Squamous Cell	4	3	0		
Small Cell	11	4	0		
Race					
Non-White	42	27	19	2.366	.306
White	5	8	3		
Sex					
Male	15	18	5	5.590	.061
Female	32	17	17		
Married					
Yes	34	24	17	.511	.775
No	13	11	5		
Antidepressant					
Yes	8	5	5	.663	.718
No	37	30	17		

Table 3:

Associations with depression as measured by the Hospital Anxiety and Depression Scale

Depression (HADS-D)		
	Univariate Analysis	
Variable	<i>r</i>	<i>p</i>
Age	.12	.38
BMI	.08	.32
Time with Disease	-.06	.75
CRP	.47	<.001
Albumin	-.35	<.001
NLR	.20	.047
	<i>F</i>	<i>P</i>
Line of Treatment	2.18	.12
1 st		
2 nd		
3 rd and beyond		
Treatment Type	5.42	.006
Chemo 6.00 (3.7) Immuno 4.9 (3.7) Targeted 2.91 (3.3)		
Disease Type	3.37	.021
Adeno 4.32 (3.8) Squamous 5.71 (3.1) Small Cell 6.72 (3.1)		
	<i>t</i>	<i>p</i>
Race	-.330	.742
non-White 5.25 (3.3) White 4.91 (3.8)		
Sex	-1.624	.107
Male 5.71 (3.9) Female 4.51 (3.6)		
Married	.902	.369
Yes 4.75 (3.6) No 5.45 (4.0)		
Antidepressant	-1.126	.263
Yes 5.83 (3.7) No 4.74 (3.7)		

Note: BMI, Body Mass Index; CRP, C-Reactive Protein; HADS-D, Hospital Anxiety and Depression Scale-Depression; NLR, neutrophil to lymphocyte ratio

Table 4:

Multivariate regression of significant demographic and treatment variables on depression as measured by the Hospital Anxiety and Depression scale.

Variable	Depression (HADS-D)			Depression (HADS-D)		
	Regression Coefficient	t value	P	Regression Coefficient	t value	P
Age	.14 (.04)	1.450	.150	.11 (.04)	1.073	.287
Sex	.14 (.78)	1.383	.170	.07 (.8)	.737	.463
C Reactive Protein (log transformed)	-	-	-	.32 (.74)	2.701	.008
Albumin	-	-	-	-.18 (1.12)	-1.599	.114
NLR (log transformed)	-	-	-	.05 (1.03)	.483	.630
Treatment Type						
Chemotherapy		Ref			Ref	
Immunotherapy	-.10 (.85)	-.909	.366	-.14 (.86)	-1.319	.191
Targeted therapy	-.24 (.98)	-2.237	.028	-.08 (1.06)	-.695	.489
Disease Type						
Adenocarcinoma		Ref			Ref	
Squamous Cell	.06 (1.43)	.620	.537	.02 (1.39)	.156	.877
Small Cell	.21 (1.07)	2.072	.041	.18 (1.03)	1.841	.069
	F 3.101 Adjusted R2 .114			F 4.052 Adjusted R2 .236		

Note: HADS-D, Hospital Anxiety and Depression Scale-Depression.